The CRP–Albumin–Lymphocyte (CALLY) index is a composite prognostic marker incorporating C-reactive protein (CRP), albumin, and lymphocyte count, reflecting systemic inflammation, nutritional status, and immune function in cancer patients. The gene discussed is ALB; the disease is cancer.